新聞Vtesse group received financing of $42M in Series A on Jan 1st '15.Cydan launched its first rare disease startup back in January 2015—Vtesse raised a total of $42 million in its series A to work on its treatment for Niemann-Pick disease type C1 disease and was later bought out for $200 million.
